OPM Biosciences 奥浦迈
27 significant filings since 30 May 2026: 7 on change of interest, 6 on equity incentive and 5 on major holder selling, and 4 other kinds. The latest, on 25 Sep 2026: 奥浦迈：关于持股5%以下特定股东减持股份计划公告. On 23 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 229.00% from the same period a year earlier.
自 30 May 2026 起有 27 份重大公告：change of interest 7 份、equity incentive 6 份、major holder selling 5 份，另有 4 类。最新一份（25 Sep 2026）：奥浦迈：关于持股5%以下特定股东减持股份计划公告。23 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 229.00%。
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥110亿 | ¥107亿 | 29th highest of 58 · 58 家中第 29 高 | |
| Trailing P/E 市盈率 | 85.9x | 31.6x | 9th highest of 35 · 35 家中第 9 高 | |
| P/B 市净率 | 3.5x | 3.1x | 24th highest of 56 · 56 家中第 24 高 | |
| Revenue Growth 营收增速 | 155.2% | 2.5% | 4th highest of 58 · 58 家中第 4 高 | |
| Profit Growth 净利增速 | 230.3% | 6.4% | 3rd highest of 58 · 58 家中第 3 高 | |
| Gross Margin 毛利率 | 46.0% | 70.5% | 16th lowest of 58 · 58 家中第 16 低 | |
| Net Margin 净利率 | 26.8% | 8.9% | 10th highest of 58 · 58 家中第 10 高 | |
| Return on Equity 净资产收益率 | 4.3% | 1.6% | 14th highest of 57 · 57 家中第 14 高 | |
| Debt to Assets 资产负债率 | 16.0% | 24.1% | 22nd lowest of 58 · 58 家中第 22 低 | |
| Grade Score 评级得分 | 73 | 50 | 3rd highest of 54 · 54 家中第 3 高 |
Statement figures are for the period to 30 Jun 2026, filed by 58 of 58 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，58 家同业中 58 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Biokin Pharmaceutical 百利天恒 | ¥988亿 | — | 21.4x | 9.4% | -874.0% | -28.9% | E |
| Remegen 荣昌生物 | ¥656亿 | 11.3x | 7.9x | 433.1% | 79.7% | 78.4% | A |
| Gan & Lee 甘李药业 | ¥439亿 | 38.2x | 3.7x | 7.6% | 27.4% | 5.2% | C |
| Junshi Biosciences 君实生物 | ¥358亿 | — | 6.0x | 45.2% | -2.4% | 0.4% | D |
| Sunshine Guojian Pharmaceutical 三生国健 | ¥351亿 | 11.4x | 4.1x | 34.8% | 42.5% | 4.3% | C |
| Shanghai RAAS Blood Products 上海莱士 | ¥331亿 | 27.4x | 1.0x | -18.8% | 20.6% | 2.0% | D |
| Chongqing Zhifei Biological Products 智飞生物 | ¥311亿 | — | 2.1x | -18.4% | -20.4% | -5.2% | D |
| Changchun High-Tech Industry 长春高新 | ¥289亿 | — | 1.3x | -16.1% | 7.9% | 2.1% | C |
| Hualan Biological Engineering 华兰生物 | ¥239亿 | 29.6x | 2.2x | -12.9% | 25.2% | 3.3% | C |
| Beijing Tiantan Biological Products 天坛生物 | ¥239亿 | 31.6x | 2.0x | -16.6% | 16.0% | 2.5% | D |
| Walvax Biotechnology 沃森生物 | ¥217亿 | 115.0x | 3.1x | -27.7% | 5.5% | 0.7% | D |
| Amoytop 特宝生物 | ¥210亿 | 19.4x | 6.8x | 21.6% | 25.9% | 13.2% | C |
| Acrobiosystems 百普赛斯 | ¥204亿 | 113.0x | 7.6x | 29.0% | 19.7% | 3.6% | B |
| Cansino Biologics 康希诺 | ¥202亿 | 496.1x | 4.1x | 43.8% | -0.1% | -0.0% | D |
| OPM Biosciences 奥浦迈 | ¥110亿 | 85.9x | 3.5x | 155.2% | 26.8% | 4.3% | B |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。